Medsider: Learn from Medtech and Healthtech Founders and CEOs
Why Early Revenue is the Most Credible Proof in Medtech: Interview with restor3d CEO Kurt Jacobus
Kurt Jacobus, CEO of restor3d, shares insights on generating early revenue and regulatory proof in medtech through the FDA's 510(b) pathway. He also covers the importance of self-regulation beyond FDA requirements and strategic investor relationship management.